Disparity in the era of personalized medicine for epithelial ovarian cancer
The treatment of high-grade serous ovarian cancer and high-grade endometrioid ovarian cancer has seen significant improvements in recent years, with BRCA1/2 and homologous recombination status guiding a personalized approach which has resulted in improved patient outcomes. However, for other epithel...
Main Authors: | Michael-John Devlin, Rowan E. Miller |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2023-01-01
|
Series: | Therapeutic Advances in Medical Oncology |
Online Access: | https://doi.org/10.1177/17588359221148024 |
Similar Items
-
Ovarian Cancer Immunotherapy and Personalized Medicine
by: Susan Morand, et al.
Published: (2021-06-01) -
The Impact of African Ancestry on Prostate Cancer Disparities in the Era of Precision Medicine
by: Deyana D. Lewis, et al.
Published: (2020-12-01) -
Biomarkers in Ovarian Cancer: Towards Personalized Medicine
by: Carlos López-Portugués, et al.
Published: (2024-03-01) -
Colorectal Cancer Biomarkers in the Era of Personalized Medicine
by: Jai N. Patel, et al.
Published: (2019-01-01) -
Serology-Based Model for Personalized Epithelial Ovarian Cancer Risk Evaluation
by: Tianqing Yan, et al.
Published: (2022-04-01)